期刊文献+

活血化瘀法对子宫内膜异位症模型大鼠E_2、P、VEGF的影响 被引量:15

Effect on Activating Blood and Removing Stasis Prescription on E_2、P、VEGF of Endometriotic Rats
下载PDF
导出
摘要 目的:探讨活血化瘀法治疗子宫内膜异位症的作用机理。方法:采用大鼠自体子宫内膜移植建立实验性子宫内膜异位症模型,分别观察活血化瘀方药和达那唑对模型大鼠外周血清E2、P含量及VEGF在大鼠异位内膜组织中的表达的影响。结果:活血化瘀方药对上述指标均有不同的降调或抑制作用,与模型组比较有显著性差异(P<0.05),活血化瘀法高剂量组与达那唑相比无显著性差异(P>0.05)。结论:活血化瘀法具有调节内分泌及血管内皮细胞生长因子作用,能够有效抑制异位子宫内膜的种植。 Objective: To study the effect and mechanism of activating blood and removing stasis prescription on treatment of endometriosis. Methods: To set up endometriosis model by rat self-endometria transplantation, E2、 P of serum and VEGF of endometriosis tissue were dividedly detected. Result: The three parameters were depressed by aetivating blood and removing stasis prescription. There was significant difference of each target between activating blood and removing stasis prescription group and model group ( P 〈 0. 05). There was no significant difference of each target between the high dose of activating blood and removing stasis prescription group and Danazol group ( P 〉 0. 05). Conclusion: activating blood and removing stasis prescription can inhibit the growth of endometrial transplants, which is relates with the VEGF of dometriotic tissue and serum hormone, especially Ea.
出处 《成都中医药大学学报》 2006年第2期28-29,33,共3页 Journal of Chengdu University of Traditional Chinese Medicine
基金 黑龙江省自然科学基金资助(No.39670895)
关键词 子宫内膜异位症 活血化瘀法 雌二醇(E2) 孕酮(P) 血管内皮细胞生长因子(VEGF) Endometriosis activating blood and removing stasis prescription E2 P vascular endothelial growth factor (VEGF)
  • 相关文献

参考文献5

  • 1Gurates B,Bulun SE.Endometriosis:The ultimate hormonal disease[J].Seminars in Reproductive Medicine,2003,21(2):125
  • 2Wu MY,Ho HN.The role of cytokines in endometriosis[J].Am J Reprod Immunol,2003,49(5):285-296
  • 3Koninckx PR,Kennedy SH,Barlow DH.Endometriotic disease:the role of peritoneal fuild[J].Hum Repoder Undate,1998,4(5):741-751
  • 4Tan XJ,Lang JH,Liu DY,et al.Expression of vascular endothelial growth factor and thrombospondin-1mRNA on patients with endometriosis[J].Fertil Steril,2002,78(1):148-153
  • 5刘木彪,何援利,彭冬先.子宫内膜异位症患者腹腔液血管内皮生长因子与内抑素的表达[J].第一军医大学学报,2004,24(1):69-71. 被引量:29

二级参考文献9

  • 1[1]Pepper MS. Manipulating angiogenesis. From basic science to the bedside[J]. Arterioscler Thromb Vasc Biol, 1997, 17(5): 605-19.
  • 2[2]American society for Reproduction Medicine. Revised American society for reproduction medicine classification of endometriosis [J].Fetil Steril, 1997, 67(8): 817-21.
  • 3[3]Dvorak HF, Brown LF, Detmar M, et al. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenasis[J]. Am J Pathol, 1995, 146(11): 1029-39.
  • 4[4]Dhanabal M, Ramchandran R, Waterman MJ, et al. Endostatin induces endothelial cell apoptosis [J]. J Biol Chem, 1999, 274(17):11721-6.
  • 5[6]Mclaren J. Vascular endothelial growth factor and endometriotic angiogenesis [ J ]. Hum Reprod Update, 2000, 6(1): 44-5.
  • 6[7]Giudice LC, Tazuke SI, Swiersz LT. Status of current research on endometriosis[J]. J Reprod Med, 1998, 43(3 Suppl): 252-62.
  • 7[9]Kupker W, Schultze-Mosgau A, Diedrich K. Paracrine changes in the peritoneal environment of women with endometriosis [J]. Hum Reprod Update, 1998, 4(5): 719-23.
  • 8[10]Barcz E, Kaminski P, Marianowski L. VEGF concentration in peritoneal fluid of patients with endometriosis [ J ]. Ginekol Pol, 2001,72(5): 442-8.
  • 9[12]Shaarawy M, E1-Sharkawy SA. Biomarkers of intrinsic angiogenic and anti-angiogenic activity in patients with endometrial hyperplasia and endometrial cancer[J]. Acta Oncol, 2001, 40(4): 513-8.

共引文献28

同被引文献139

引证文献15

二级引证文献68

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部